The Effects of Dietary Intervention on Gastrointestinal Function in Patients With Anorexia Nervosa and Obesity

• Sponsor: University of Zurich (Other)
• Overall Status: Completed
• CT.gov ID: NCT00946816
• Collaborator: Schweizerischer Nationalfonds (Other)
• Enrollment: 60
• Location: 1
• Arms: 3
• Duration (Months): 26
• Patients Per Site Per Month: 2.3

Study Details

Study Description

Brief Summary

Diseases characterized by abnormal low and high body weight are common in the community and are associated with significant morbidity, mortality and health care related costs.

Genetic, dietary, social and psychologic factors all play an important part in these conditions; however the central role of gastrointestinal (GI) function and the control of nutrient delivery to the small bowel has not been well described in health or disease.

We propose that the GI response to feeding varies inversely with body weight. This hypothesis predicts that as body weight increases, the response to a given meal decreases in terms of motility, neurohormonal feedback, sensation and satiety. This provides an attractive explanation for why thin individuals stop eating after a small amount of food (i.e. limited gastric relaxation, rapid gastric emptying, powerful nutrient feedback with early satiety)and, conversely, why obese patients continue to eat even after nutritional requirements have been met (i.e. large gastric relaxation, slow gastric emptying, weak nutrient feedback with delayed satiety).

This project will apply MRI and Breath Tests to assess GI motility, hormonal feedback, visceral sensation and satiety in patients with pathologically low (anorexia nervosa) and high (morbid obesity) body weight and in healthy, normal weight controls.

Participants will include: Group A: normal weight, healthy volunteers (n=24: BMI: 18.5-24.9 kg/m2) Group B: patients with anorexia nervosa (DSMIV criteria and BMI: <16 kg/m2) B1: anorexia restricting type (n=12-20 over 2 years) and B2: anorexia bulimia type (n=20 over 2 years) Group C: patients with morbid obesity (BMI: 30-40 kg/m2) C1: obese (n=20 over 2 years) and C2: obese with DM type II (n=20 over 2 years).

Two studies will be performed

1. Cross-sectional study: The effects of a test meal on GI motility, hormonal feedback, visceral sensation and satiety in healthy controls and in patients with anorexia and obesity

2. Longitudinal study: The effects of dietary treatment (i.e. weight change) on GI motility, hormonal feedback, visceral sensation and satiety in patients with anorexia and obesity

Condition or Disease	Intervention/Treatment	Phase
Anorexia Nervosa; Obesity; Healthy Participants	Behavioral: Nutritional Intervention	N/A

Study Design

• Study Type: Interventional
• Actual Enrollment: 60 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: The Effects of Dietary Intervention on Gastrointestinal Motility, Hormonal Feedback, Visceral Sensation and Satiety in Patients With Anorexia Nervosa and Obesity
• Study Start Date: Sep 1, 2010
• Actual Primary Completion Date: Nov 1, 2012
• Actual Study Completion Date: Nov 1, 2012

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Anorexia Nervosa	Behavioral: Nutritional Intervention; Nutritional Intervention
Active Comparator: Obesity	Behavioral: Nutritional Intervention; Nutritional Intervention
Active Comparator: Healthy volunteers	Behavioral: Nutritional Intervention; Nutritional Intervention

Outcome Measures

Primary Outcome Measures

1. The GI response to a given meal in terms of: motility, neurohormonal feedback, sensation and satiety [2 years]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 40 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

In addition to satisfying specific DSMIV criteria for anorexia nervosa (B1, B2) or WHO criteria for obesity (C1), or obesity and diabetes mellitus type II (C2), general inclusion criteria include:

• aged at least 18 and not more than 40 years

• able to communicate well with the investigators and provide written consent

• no physical co-morbidity requiring active treatment, in particular diabetes mellitus, impairment of liver or kidney function (subjects with diabetes mellitus type II are eligible for study group C2)

• no psychiatric (DSM IV) disorders limiting the ability to comply with study requirements

• no use of medications influencing upper GI motility within one week of the study (i.e. nitrates, prokinetic drugs, macrolide antibiotics). Acid suppression and antihypertensive medication beta-blocker, calcium channel blockers are acceptable.

• no evidence of current drug or alcohol abuse

• no history of gastrointestinal disease or surgery except appendicectomy or hernia repair

• females will take a urine pregnancy test before each study, any participant with a positive pregnancy test will be excluded (females will be investigated always in the same menstrual phase)

Exclusion criteria:

• pregnancy

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University Hospital Zurich, Gastroenterology and Hepatology	Zurich	ZH	Switzerland	8091

Sponsors and Collaborators

• University of Zurich
• Schweizerischer Nationalfonds

Investigators

• Principal Investigator: Michael Fried, Professor MD, University Hospital Zurich, Gastroenterology and Hepatology

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: University of Zurich
• ClinicalTrials.gov Identifier: NCT00946816
• Other Study ID Numbers: SNF 320030_1253331
• First Posted: Jul 27, 2009
• Last Update Posted: Nov 14, 2012
• Last Verified: Nov 1, 2012

• Additional relevant MeSH terms: Obesity; Anorexia; Anorexia Nervosa

Study Results

No Results Posted as of Nov 14, 2012